KRAS and neoplasm: In our patients’ cohort, no significant relationships were observed between KRAS tumor mutation status and smoking history (p = 0.508), number of metastatic organs (p = 0.226), histologic subtype (p = 0.765), performance status (p = 0.340), gender (p = 0.791) and PD-L1 status (p = 0.214).